Mario Alberto Accardi net worth and biography

Mario Accardi Biography and Net Worth

President of the Orexin Program of Centessa Pharmaceuticals

Dr. Mario Alberto Accardi is the President of the Orexin Program at Centessa Pharmaceuticals. Most recently, he was the CEO and Founder of Orexia Therapeutics, a neuroscience company harnessing advanced structural biology technologies to discover and develop orexin agonists for narcolepsy and other sleep wake disorders. At Orexia, he successfully raised a €40M Series A, established multiple strategic partnerships, and led the company to acquisition by Centessa Pharmaceuticals in 2021.

Previously, Mario was in life sciences venture capital as an Investment Associate at Entrepreneurs Fund, and later as a Venture Partner at Fort Rock Capital. In these roles, he led deals in pre-clinical and clinical stage biotech companies across different therapeutic areas.

Earlier in his career, Mario founded and led Imperial College spin-out medtech company Orthonika.

Mario holds a Postgraduate in Genomic Medicine, a PhD in Biomedical Engineering, and a First-Class Honours MEng Degree in Mechanical Engineering from Imperial College London.

What is Mario Alberto Accardi's net worth?: The estimated net worth of Mario Alberto Accardi is at least $4.83 million as of December 8th, 2025. Dr. Accardi owns 178,801 shares of Centessa Pharmaceuticals stock worth more than $4,831,561 as of December 12th. This net worth evaluation does not reflect any other assets that Dr. Accardi may own. Learn More about Mario Alberto Accardi's net worth.
How do I contact Mario Alberto Accardi?: The corporate mailing address for Dr. Accardi and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on Mario Alberto Accardi's contact information.
Has Mario Alberto Accardi been buying or selling shares of Centessa Pharmaceuticals?: Within the last three months, Mario Alberto Accardi has sold $500,000.00 in Centessa Pharmaceuticals stock. Most recently, Mario Alberto Accardi sold 10,000 shares of the business's stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a transaction totalling $300,000.00. Following the completion of the sale, the insider now directly owns 178,801 shares of the company's stock, valued at $5,364,030. Learn More on Mario Alberto Accardi's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Mario Accardi (President of the Orexin Program), Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), Arjun Goyal (Director), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, Centessa Pharmaceuticals insiders bought shares 2 times. They purchased a total of 462,585 shares worth more than $5,866,686.94. In the last year, insiders at the sold shares 45 times. They sold a total of 895,870 shares worth more than $15,447,842.20. The most recent insider tranaction occured on December, 8th when insider Mario Alberto Accardi sold 10,000 shares worth more than $300,000.00. Insiders at Centessa Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 12/8/2025.

Mario Alberto Accardi Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/8/2025	Sell	10,000	$30.00	$300,000.00	178,801
10/27/2025	Sell	8,000	$25.00	$200,000.00	194,394
9/16/2025	Sell	8,172	$21.40	$174,880.80	197,394
9/9/2025	Sell	7,000	$20.00	$140,000.00	205,566
7/29/2025	Sell	8,322	$15.23	$126,744.06	208,163
6/24/2025	Sell	15,000	$14.00	$210,000.00	216,485

Mario Alberto Accardi Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $26.51

$25.59

$27.67

50 Day Range

MA: $25.57

$22.12

$29.91

2 Week Range

Now: $26.51

$9.60

$30.58

Volume

2,412,417 shs

Average Volume

1,716,311 shs

Market Capitalization

$3.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55